Literature DB >> 2391068

Prevalence and prediction of osteopenia in chronic liver disease.

H L Bonkovsky1, M Hawkins, K Steinberg, T Hersh, J T Galambos, J M Henderson, W J Millikan, J R Galloway.   

Abstract

To obtain information on the prevalence and clinical and laboratory correlates of osteopenia in patients with chronic liver disease, we measured bone densities and 30 selected laboratory variables in 133 subjects (70 men, 63 women) with liver disease. Thirty-two had alcoholic liver disease, 18 had primary biliary cirrhosis, 16 had primary sclerosing cholangitis, 48 had other forms of cirrhosis (cryptogenic, posthepatic) and 19 had chronic hepatitis or fibrosis without cirrhosis. Bone densities of the lumbar spine and three sites of the proximal femur (neck, Ward's triangle, greater trochanter) were estimated by dual-photon absorptiometry. Bone densities at all sites were significantly correlated to one another (r = 0.4 to 0.9; 95% confidence intervals = 0.24-0.54 to 0.81-0.90; p less than 0.0001 for all). Compared with an age- and gender-matched reference group, patients with liver disease had highly significant decreases in bone densities (greater than 2 standard deviations below control values; p less than 0.0008 at all sites). Decreases were particularly marked (24% to 42%) at Ward's triangle, the site of the femoral neck particularly prone to fracture. The prevalence of decreased bone densities ranged from 10% to 56%, depending on the site studied and the nature of the liver disease. Among 30 laboratory variables studied, there were significant (p less than 0.05) correlations with bone densities at more than one site for urinary creatinine (r = 0.21, 0.25), urinary calcium (r = -0.18, -0.23), serum total alkaline phosphatase (r = -0.18, -0.27) and the liver-1 isozyme of serum alkaline phosphatase (r = -0.19, -0.26).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2391068     DOI: 10.1002/hep.1840120214

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Osteoporosis in chronic liver disease.

Authors:  J Heathcote
Journal:  Curr Gastroenterol Rep       Date:  1999-12

3.  Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.

Authors:  Karam A Mahdy; Hanaa H Ahmed; Fathia Mannaa; Azza Abdel-Shaheed
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

4.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Bone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study.

Authors:  G Y Minuk; R Greenberg; J Uhanova; K Hawkins; W D Leslie
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

Review 6.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

7.  Bone mineral density in children with cirrhosis.

Authors:  Nuray Uslu; Inci Nur Saltik-Temizel; Hülya Demir; Yusuf Usta; Hasan Ozen; Figen Gürakan; Aysel Yüce; Nurten Koçak
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 8.  Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis.

Authors:  Chang Seok Bang; In Soo Shin; Sung Wha Lee; Jin Bong Kim; Gwang Ho Baik; Ki Tae Suk; Jai Hoon Yoon; Yeon Soo Kim; Dong Joon Kim
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

9.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 10.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.